[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0811248A2 - Formulação de antraciclina de baixa viscosidade. - Google Patents

Formulação de antraciclina de baixa viscosidade.

Info

Publication number
BRPI0811248A2
BRPI0811248A2 BRPI0811248-7A2A BRPI0811248A BRPI0811248A2 BR PI0811248 A2 BRPI0811248 A2 BR PI0811248A2 BR PI0811248 A BRPI0811248 A BR PI0811248A BR PI0811248 A2 BRPI0811248 A2 BR PI0811248A2
Authority
BR
Brazil
Prior art keywords
low viscosity
anthracycline
formulation
anthracycline formulation
viscosity
Prior art date
Application number
BRPI0811248-7A2A
Other languages
English (en)
Inventor
Felix Kratz
Original Assignee
Ktb Tumorforschungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ktb Tumorforschungs Gmbh filed Critical Ktb Tumorforschungs Gmbh
Publication of BRPI0811248A2 publication Critical patent/BRPI0811248A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
BRPI0811248-7A2A 2007-05-16 2008-05-16 Formulação de antraciclina de baixa viscosidade. BRPI0811248A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07009865 2007-05-16
PCT/EP2008/003969 WO2008138646A1 (en) 2007-05-16 2008-05-16 Low-viscous anthracycline formulation

Publications (1)

Publication Number Publication Date
BRPI0811248A2 true BRPI0811248A2 (pt) 2014-11-04

Family

ID=39705201

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811248-7A2A BRPI0811248A2 (pt) 2007-05-16 2008-05-16 Formulação de antraciclina de baixa viscosidade.

Country Status (11)

Country Link
US (1) US8703724B2 (pt)
EP (1) EP2152312B1 (pt)
JP (1) JP5634862B2 (pt)
KR (1) KR20100029764A (pt)
CN (1) CN101743020A (pt)
AU (1) AU2008250518B2 (pt)
BR (1) BRPI0811248A2 (pt)
CA (1) CA2687291A1 (pt)
CO (1) CO6251276A2 (pt)
MX (1) MX2009012370A (pt)
WO (1) WO2008138646A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846882B2 (en) * 2011-04-29 2014-09-30 Synbias Pharma Ag Method of producing 4-demethoxydaunorubicin
CN104203252A (zh) * 2012-04-09 2014-12-10 日本迈科洛生物制药有限公司 注射剂用组合物
US20150342975A1 (en) * 2012-12-13 2015-12-03 Cytrx Corporation Anthracycline formulations
CA2912908C (en) 2013-06-05 2021-06-08 Cytrx Corporation Cytotoxic agents comprising covalently protein binding groups for treating brain cancer
CN104434818B (zh) * 2014-11-08 2017-08-08 山东新时代药业有限公司 一种注射用盐酸柔红霉素
NZ738229A (en) * 2015-06-19 2024-07-05 Ladrx Corp Delivery systems for controlled drug release
CN118852324A (zh) 2017-11-30 2024-10-29 拉德克斯公司 澳瑞他汀e衍生物的白蛋白结合产物
US11572373B2 (en) 2017-11-30 2023-02-07 Ladrx Corporation Maytansinoid-based drug delivery systems

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4043997A (en) * 1976-05-28 1977-08-23 Cutter Laboratories, Inc. Method for isolating albumin using insoluble supports coupled to a dye
US5157044A (en) * 1983-02-04 1992-10-20 University Of Iowa Research Foundation Analogs of carbonic anhydrase inhibitors and their use as topical IOP inhibitors
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US6267964B1 (en) * 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5166319A (en) 1989-10-10 1992-11-24 Brunswick Corporation Interfacial condensation of bioactive compounds and the site-specific compounds and conjugates thereof
EP0493745A1 (en) 1990-12-21 1992-07-08 Dojindo Laboratories Fluorescent compound, complex, reagent, and specific binding assay employing said reagent
US5622929A (en) * 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
JP2915252B2 (ja) * 1993-06-30 1999-07-05 明治製菓株式会社 溶解性が改善された製剤の製造法
AU1140495A (en) * 1994-01-27 1995-08-03 Bristol-Myers Squibb Company Method for preparing thioether conjugates
US5612474A (en) * 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
WO1996039183A1 (en) 1995-05-31 1996-12-12 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector molecules
WO2000002050A1 (en) 1998-07-07 2000-01-13 Department Of Radiation Oncology, University Of Washington Trifunctional reagent for conjugation to a biomolecule
IT1282625B1 (it) 1996-02-14 1998-03-31 Zambon Spa Composizione farmaceutica atta ad inibire la formazione di metastasi tumorali
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US5780446A (en) * 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
ATE298344T1 (de) 1996-08-27 2005-07-15 Univ Utah Res Found Biokonjugate und verabreichung von bioaktiven substanzen
DE19636889A1 (de) * 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
CN1273476C (zh) 1997-09-12 2006-09-06 埃克西康有限公司 寡核苷酸类似物
DE19923168A1 (de) 1999-05-20 2000-11-23 Roche Diagnostics Gmbh Neue Fluoreszenzfarbstoffe und ihre Verwendung als Fluoreszenzmarker
JP4342941B2 (ja) * 2001-08-29 2009-10-14 中外製薬株式会社 抗体含有安定化製剤
KR100774366B1 (ko) * 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
ES2337563T3 (es) * 2002-12-31 2010-04-27 Zydus Bsv Pharma Private Limited Liposomas no pegilados de circulacion duradera.

Also Published As

Publication number Publication date
EP2152312A1 (en) 2010-02-17
US20100152273A1 (en) 2010-06-17
US8703724B2 (en) 2014-04-22
JP5634862B2 (ja) 2014-12-03
KR20100029764A (ko) 2010-03-17
AU2008250518A1 (en) 2008-11-20
JP2010526845A (ja) 2010-08-05
CN101743020A (zh) 2010-06-16
EP2152312B1 (en) 2014-12-31
CA2687291A1 (en) 2008-11-20
MX2009012370A (es) 2010-04-22
CO6251276A2 (es) 2011-02-21
AU2008250518B2 (en) 2013-09-12
WO2008138646A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
BRPI0813235A2 (pt) Combinação anti-helmíntica.
BRPI0814745A2 (pt) Composição de produto.
BRPI0815717A2 (pt) Compostos de imidazopirazina.
FR2909857B1 (fr) Endovalve.
BRPI0915731A2 (pt) composição de graxa.
BRPI0812354A2 (pt) Composição farmacêutica não-aquosa.
BRPI0915732A2 (pt) composição de graxa.
BRPI0813448A2 (pt) Combinações de pesticidas.
BRPI0923047A2 (pt) "conjugados de proteínas-oligossacarídeos".
BRPI0716046A2 (pt) composiÇÕes de nanopartÍcula.
BRPI0816684A2 (pt) Estrutura de painel.
BRPI0918637A2 (pt) composição antimicrobiana.
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
BRPI0811248A2 (pt) Formulação de antraciclina de baixa viscosidade.
BRPI0917990A2 (pt) formulação em gel antimicrobianas.
BRPI0816679A2 (pt) Derivados de ftalazinona.
BRPI0920870A2 (pt) antibióticos de oxazolidinila.
FR2923713B1 (fr) Composition reductrice epaissie.
BRPI0811851A2 (pt) Dispositivo de dispensação.
FR2925319B1 (fr) Composition cosmetique tenseur.
BRPI0811431A2 (pt) Composição farmacêutica aquosa.
CL2007002130S1 (es) Dispensador.
NL1034526A1 (nl) Emoticoninrichting.
ITCE20060002A1 (it) Patok.
FR2914939B1 (fr) Arret de vantail.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]